Sugiura Kiyoaki, Kato Tatsuki, Aoyama Junya, Oshima Go, Kikuchi Hiroto, Okabayashi Koji, Aiko Satoshi, Kitagawa Yuko
Department of Surgery, Eiju General Hospital, 2-23-16 Higashiueno, Taito-Ku, Tokyo, 110-8645, Japan.
Department of Surgery, Kawasaki Municipal Hospital, Kawasaki, Kanagawa, Japan.
Int J Clin Oncol. 2025 Oct;30(10):2032-2042. doi: 10.1007/s10147-025-02845-8. Epub 2025 Jul 29.
Primary tumor resection is an option for patients with stage IV colorectal cancer (CRC). However, there is still no reliable strategy for predicting the survival of individual patients undergoing primary tumor resection (PTR). The aim of this study was to identify predictors of good prognosis in patients with stage IV CRC with PTR.
This is a retrospective analysis of patients with stage IV CRC who had undergone PTR in the Keio Surveillance Epidemiology and End Results (K-SEER) database. Clinical data and short- and long-term outcomes were analyzed. Univariate and multivariate analyses were performed using Cox proportional hazards model including all survival-related variables.
Among 252 patients enrolled in this study, 176 had single-organ and 76 had multi-organ metastases. Seventy-seven patients did not receive chemotherapy after primary tumor resection. Three patients consequently underwent curative metastasectomy after PTR. Multivariate Cox analysis revealed age, number of organs with metastasis, and chemotherapy after PTR were independently associated with both Overall Survival (OS) and Cancer-Specific Survival (CSS). In the subgroup analysis, the survival rate was significantly lower in patients with multi-organ metastases than in those with single-organ metastases, both in 3-year OS (47.69% vs 23.20%; log-rank P < 0.001) and 3-year CSS (54.45% vs 30.48%; log-rank P < 0.001).
This study demonstrated that multi-organ metastasis was a prognostic factor for poor prognosis in patients with stage IV CRC patients who underwent PTR. These findings could support surgeons to make better clinical decisions for patients with stage IV CRC.
对于IV期结直肠癌(CRC)患者,原发肿瘤切除是一种治疗选择。然而,目前仍没有可靠的策略来预测接受原发肿瘤切除(PTR)的个体患者的生存情况。本研究的目的是确定接受PTR的IV期CRC患者预后良好的预测因素。
这是一项对在庆应义塾大学监测、流行病学和最终结果(K-SEER)数据库中接受PTR的IV期CRC患者的回顾性分析。分析了临床数据以及短期和长期结局。使用包含所有生存相关变量的Cox比例风险模型进行单因素和多因素分析。
在本研究纳入的252例患者中,176例有单器官转移,76例有多器官转移。77例患者在原发肿瘤切除后未接受化疗。其中3例患者在PTR后接受了根治性转移灶切除术。多因素Cox分析显示,年龄、转移器官数量以及PTR后化疗与总生存期(OS)和癌症特异性生存期(CSS)均独立相关。在亚组分析中,多器官转移患者的生存率显著低于单器官转移患者,3年OS(47.69%对23.20%;对数秩检验P<0.001)和3年CSS(54.45%对30.48%;对数秩检验P<0.001)均如此。
本研究表明,多器官转移是接受PTR的IV期CRC患者预后不良的一个预后因素。这些发现可为外科医生为IV期CRC患者做出更好的临床决策提供依据。